{"id":"https://openalex.org/W7148961024","doi":"https://doi.org/10.1158/1538-7445.am2026-5791","title":"Abstract 5791: Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment of clear cell renal cell carcinoma","display_name":"Abstract 5791: Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment of clear cell renal cell carcinoma","publication_year":2026,"publication_date":"2026-04-03","ids":{"openalex":"https://openalex.org/W7148961024","doi":"https://doi.org/10.1158/1538-7445.am2026-5791"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2026-5791","doi":"https://doi.org/10.1158/1538-7445.am2026-5791","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-5791","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5132850792","display_name":"J. Scott Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Scott Lee","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091760868","display_name":"Michelle S. Cruz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle S. Cruz","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107377374","display_name":"Isabella P. Tran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabella Tran","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055081056","display_name":"Kevin Chiu","orcid":"https://orcid.org/0000-0002-9087-8153","observed_orcids":["https://orcid.org/0000-0002-9087-8153"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Chiu","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083931000","display_name":"Jennifer K. Griffin","orcid":"https://orcid.org/0000-0001-8390-7502","observed_orcids":["https://orcid.org/0000-0001-8390-7502"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Griffin","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035112314","display_name":"Andres H. de la Pe\u00f1a","orcid":"https://orcid.org/0000-0002-2368-6944","observed_orcids":["https://orcid.org/0000-0002-2368-6944"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andres H de la Pe\u00f1a","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016758075","display_name":"Kurt Januszyk","orcid":"https://orcid.org/0000-0002-9076-4180","observed_orcids":["https://orcid.org/0000-0002-9076-4180"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kurt Januszyk","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132889266","display_name":"Xiaoxi Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoxi Liu","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041965133","display_name":"Bryan S. Lee","orcid":"https://orcid.org/0000-0002-2601-5783","observed_orcids":["https://orcid.org/0000-0002-2601-5783"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Lee","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132913393","display_name":"Anthony Burt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Burt","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053227790","display_name":"John E. Tellew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Tellew","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132902906","display_name":"Mengyu Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mengyu Wu","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Leslie Watson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leslie Watson","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026797976","display_name":"Ana Dominguez-Andres","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana Dominguez-Andres","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132918639","display_name":"Ling Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Huang","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132921807","display_name":"Randy Soriano","orcid":"https://orcid.org/0000-0002-3442-4464","observed_orcids":["https://orcid.org/0000-0002-3442-4464"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randy Soriano","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132845734","display_name":"Devin Knece","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Devin Knece","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070978616","display_name":"Molly FitzGibbon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly FitzGibbon","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132884153","display_name":"Jake Fathman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jake Fathman","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132867289","display_name":"Celin Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Celin Sanchez","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132854422","display_name":"Nathalia Cruz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathalia Cruz","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132849951","display_name":"Zac Neiman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zac Neiman","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132839646","display_name":"Ana Grant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana Grant","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064013294","display_name":"Mary E. Matyskiela","orcid":"https://orcid.org/0000-0002-8953-7263","observed_orcids":["https://orcid.org/0000-0002-8953-7263","https://orcid.org/0009-0002-6731-3215"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Matyskiela","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132879210","display_name":"Rohan Beckwith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rohan Beckwith","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012991889","display_name":"Ben G. Wen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ben Wen","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132907829","display_name":"Klaus Wagner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Klaus Wagner","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005830512","display_name":"Philip P. Chamberlain","orcid":"https://orcid.org/0000-0002-6407-7344","observed_orcids":["https://orcid.org/0000-0002-6407-7344"]},"institutions":[{"id":"https://openalex.org/I4387152356","display_name":"Neomorph","ror":"https://ror.org/00dtsha18","country_code":"US","type":"company","lineage":["https://openalex.org/I4387152356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip Chamberlain.","raw_affiliation_strings":["Neomorph, Inc, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neomorph, Inc, San Diego, CA","institution_ids":["https://openalex.org/I4387152356"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4387152356"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"7_Supplement","first_page":"5791","last_page":"5791"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9077000021934509,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9077000021934509,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.062300000339746475,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.007400000002235174,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/molecular-glue-degraders","display_name":"molecular glues","score":0.8500000238418579},{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.9900000095367432},{"id":"https://openalex.org/keywords/vhl-deficiency","display_name":"VHL deficiency","score":0.7300000190734863},{"id":"https://openalex.org/keywords/hif-2alpha","display_name":"HIF-2\u03b1","score":0.9179999828338623},{"id":"https://openalex.org/keywords/hif-1alpha","display_name":"HIF-1\u03b1","score":0.9390000104904175},{"id":"https://openalex.org/keywords/cereblon","display_name":"cereblon","score":0.6700000166893005},{"id":"https://openalex.org/keywords/bhlh-pas-proteins","display_name":"bHLH-PAS proteins","score":0.843999981880188},{"id":"https://openalex.org/keywords/aryl-hydrocarbon-receptor","display_name":"aryl hydrocarbon receptor","score":0.8980000019073486},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.7609999775886536},{"id":"https://openalex.org/keywords/cyclin-d","display_name":"cyclin D","score":0.9279999732971191},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.49900001287460327},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.3149999976158142},{"id":"https://openalex.org/keywords/proteomics","display_name":"proteomics","score":0.3630000054836273}],"concepts":[{"id":"https://openalex.org/C45815257","wikidata":"https://www.wikidata.org/wiki/Q109984923","display_name":"Aryl hydrocarbon receptor nuclear translocator","level":5,"score":0.8809999823570251},{"id":"https://openalex.org/C2781278892","wikidata":"https://www.wikidata.org/wiki/Q18556340","display_name":"Clear cell renal cell carcinoma","level":3,"score":0.7860000133514404},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.723800003528595},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.564300000667572},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.482699990272522},{"id":"https://openalex.org/C162317418","wikidata":"https://www.wikidata.org/wiki/Q252857","display_name":"Transcriptome","level":4,"score":0.4629000127315521},{"id":"https://openalex.org/C33594762","wikidata":"https://www.wikidata.org/wiki/Q155750","display_name":"Aryl hydrocarbon receptor","level":4,"score":0.46230000257492065},{"id":"https://openalex.org/C160450060","wikidata":"https://www.wikidata.org/wiki/Q104598479","display_name":"Hypoxia-inducible factors","level":3,"score":0.41440001130104065},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.40549999475479126},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40450000762939453},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.3939000070095062},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.38749998807907104},{"id":"https://openalex.org/C2778560582","wikidata":"https://www.wikidata.org/wiki/Q18347894","display_name":"Clear cell","level":3,"score":0.362199991941452},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.3569999933242798},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3490999937057495},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.34389999508857727},{"id":"https://openalex.org/C27153228","wikidata":"https://www.wikidata.org/wiki/Q3787274","display_name":"Transcriptional regulation","level":4,"score":0.31299999356269836},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.30300000309944153},{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.2994999885559082},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2912999987602234},{"id":"https://openalex.org/C2778264664","wikidata":"https://www.wikidata.org/wiki/Q422445","display_name":"Tumor suppressor gene","level":4,"score":0.28630000352859497},{"id":"https://openalex.org/C31194975","wikidata":"https://www.wikidata.org/wiki/Q20970095","display_name":"HIF1A","level":3,"score":0.28130000829696655},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.2809999883174896},{"id":"https://openalex.org/C134320426","wikidata":"https://www.wikidata.org/wiki/Q901026","display_name":"Chromatin immunoprecipitation","level":5,"score":0.27720001339912415},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.2734000086784363},{"id":"https://openalex.org/C2779733811","wikidata":"https://www.wikidata.org/wiki/Q5531562","display_name":"Gene signature","level":4,"score":0.26499998569488525},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.26159998774528503},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.2615000009536743},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.2508000135421753}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2026-5791","doi":"https://doi.org/10.1158/1538-7445.am2026-5791","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-5791","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7148665560","https://openalex.org/W7161278160","https://openalex.org/W2582388243","https://openalex.org/W2021673694","https://openalex.org/W7160448497","https://openalex.org/W2514212469","https://openalex.org/W4321375611","https://openalex.org/W4403315002","https://openalex.org/W2024542453","https://openalex.org/W4405782704"],"abstract_inverted_index":{"Abstract":[0],"A":[1],"hallmark":[2],"of":[3,12,29,46,59,63,75,140,151,157,193,204,222,260,271,340,347,352,361],"clear":[4,353],"cell":[5,7,38,169,200,354,356],"renal":[6,355],"carcinoma":[8,357],"(ccRCC)":[9],"is":[10],"inactivation":[11],"the":[13,57,73,81,137,258,269,350,362],"von":[14],"Hippel-Lindau":[15],"tumor":[16],"suppressor":[17],"gene":[18],"(VHL).":[19],"Deficiency":[20],"in":[21,24,50,80,166,171,174,244],"VHL":[22],"results":[23],"aberrant":[25],"stabilization":[26],"and":[27,33,41,145,173,185,211,235],"activation":[28],"hypoxia-inducible":[30],"factors":[31],"1\u03b1":[32],"2\u03b1":[34],"(HIF-1\u03b1/2\u03b1)":[35],"promoting":[36],"cancer":[37],"survival,":[39],"metastasis,":[40],"angiogenesis.":[42],"The":[43],"therapeutic":[44,266],"value":[45],"targeting":[47],"hypoxia":[48],"signaling":[49],"ccRCC":[51,168,199],"has":[52],"been":[53],"clinically":[54],"validated":[55],"by":[56,78,226],"development":[58],"small":[60,82],"molecule":[61,83],"inhibitors":[62],"HIF-2\u03b1.":[64],"However,":[65],"subsequent":[66],"studies":[67],"have":[68],"also":[69,103,218],"uncovered":[70],"susceptibility":[71],"to":[72,112],"onset":[74],"resistance":[76],"conferred":[77],"mutations":[79],"binding":[84],"pocket.":[85],"As":[86],"class":[87,108],"I":[88,229],"basic":[89],"helix-loop-helix":[90],"PER/ARNT/SIM":[91],"(bHLH-PAS)":[92],"proteins,":[93],"HIF-1\u03b1/2\u03b1":[94],"require":[95],"heterodimerization":[96],"with":[97,154],"aryl":[98,236],"hydrocarbon":[99,237],"nuclear":[100],"translocator":[101],"(ARNT,":[102],"known":[104],"as":[105,132,263],"HIF-1\u03b2,":[106],"a":[107,120,142,264,342],"II":[109],"bHLH-PAS":[110,230],"protein)":[111],"exert":[113],"their":[114],"transcriptional":[115],"activity.":[116,128],"Consequently,":[117],"ARNT":[118,164,261,348],"represents":[119],"viable":[121],"alternative":[122],"target":[123,206,223],"for":[124,268,349,365],"disrupting":[125],"oncogenic":[126],"HIF":[127],"While":[129],"traditionally":[130],"regarded":[131],"undruggable,":[133],"here":[134],"we":[135],"highlight":[136,257],"preclinical":[138],"characterization":[139,339],"NEO-811,":[141,341],"potent,":[143],"selective,":[144],"orally":[146],"bioavailable":[147],"molecular":[148,344],"glue":[149,345],"degrader":[150,346],"ARNT.":[152],"Consistent":[153],"its":[155],"mechanism":[156],"action,":[158],"NEO-811":[159,181,194,217,241],"induced":[160],"rapid,":[161],"cereblon":[162],"(CRBN)-dependent":[163],"depletion":[165],"multiple":[167],"lines":[170,201],"vitro":[172],"vivo.":[175],"Global":[176],"proteomics":[177],"analysis":[178],"confirmed":[179,202],"that":[180,248],"was":[182],"highly":[183],"selective":[184],"did":[186],"not":[187],"degrade":[188],"well-known":[189],"neosubstrates.":[190],"Transcriptomic":[191],"profiling":[192],"activity":[195,243],"across":[196],"several":[197],"VHL-deficient":[198,272],"suppression":[203],"HIF-2\u03b1":[205,245],"genes,":[207],"including":[208,233],"cyclin":[209],"D":[210],"vascular":[212],"endothelial":[213],"growth":[214],"factor":[215],"(VEGF).":[216],"uniquely":[219],"suppressed":[220],"expression":[221],"genes":[224],"regulated":[225],"other":[227],"Class":[228],"transcription":[231],"factors,":[232],"HIF-1\u03b1":[234],"receptor":[238],"(AHR).":[239],"Critically,":[240],"retained":[242],"inhibitor-resistant":[246],"cells":[247],"harbored":[249],"previously":[250],"described":[251],"mutations.":[252],"In":[253],"conclusion,":[254],"our":[255],"findings":[256],"potential":[259],"degradation":[262],"promising":[265],"modality":[267],"treatment":[270,351],"ccRCC.":[273],"Citation":[274],"Format:":[275],"J.":[276],"Scott":[277],"Lee,":[278,298],"Michelle":[279],"S.":[280],"Cruz,":[281,322],"Isabella":[282],"Tran,":[283],"Kevin":[284],"Chiu,":[285],"Jennifer":[286],"Griffin,":[287],"Andres":[288],"H":[289],"de":[290],"la":[291],"Pe\u00f1a,":[292],"Kurt":[293],"Januszyk,":[294],"Xiaoxi":[295],"Liu,":[296],"Bryan":[297],"Anthony":[299],"Burt,":[300],"John":[301],"Tellew,":[302],"Mengyu":[303],"Wu,":[304],"Leslie":[305],"Watson,":[306],"Ana":[307,325],"Dominguez-Andres,":[308],"Ling":[309],"Huang,":[310],"Randy":[311],"Soriano,":[312],"Devin":[313],"Knece,":[314],"Molly":[315],"FitzGibbon,":[316],"Jake":[317],"Fathman,":[318],"Celin":[319],"Sanchez,":[320],"Nathalia":[321],"Zac":[323],"Neiman,":[324],"Grant,":[326],"Mary":[327],"Matyskiela,":[328],"Rohan":[329],"Beckwith,":[330],"Ben":[331],"Wen,":[332],"Klaus":[333],"Wagner,":[334],"Philip":[335],"Chamberlain.,":[336],".":[337],"Preclinical":[338],"novel":[343],"[abstract].":[358],"In:":[359],"Proceedings":[360],"American":[363],"Association":[364],"Cancer":[366,384],"Research":[367],"Annual":[368],"Meeting":[369],"2026;":[370],"Part":[371],"1":[372],"(Regular":[373],"Abstracts);":[374],"2026":[375],"Apr":[376],"17-22;":[377],"San":[378],"Diego,":[379],"CA.":[380],"Philadelphia":[381],"(PA):":[382],"AACR;":[383],"Res":[385],"2026;86(7":[386],"Suppl):Abstract":[387],"nr":[388],"5791.":[389]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-04-04T00:00:00"}